000			01005nam a2200121Ia 4500
008			220620s9999||||xx |||||||||||||| ||und||
245		0	_aOutcomes and Therapeutic Management of Bladder Cancer
546			_aEnglish[eng]
650			_abladder cancer||robotic-assisted||open||radical cystectomy||survival||propensity score||age||urothelial carcinoma||outcome||anesthesia recovery periods||cognitive impairment||gamma-cyclodextrins||neuromuscular blockade||robotic radical cystectomy||glycogen||clear-cell adenocarcinoma||urinary bladder||SEER program database||female||intracorporeal neobladder||outcomes||robotic||sex-sparing||methylation||biomarkers||FOXA1||GATA3||KRT20||molecular markers||mRNA||muscle-invasive bladder cancer||PCR||human epidermal growth factor receptor 2||indoleamine 2,3-dioxygenase||programmed death ligand-1||immunotherapy||nodal disease||pN1||neoadjuvant||adjuvant||chemotherapy||n/a
700			_aMoschini, Marco
856			_uhttps://mdpi.com/books/pdfview/book/2848
942			_cEB
999			_c33318 _d33318